557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients

BACKGROUND: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Hydroxychloroquine (HQN) is an experimental treatment for COVID-19. Effects of coadministration of HQN with RDV have not been studied and are relevant given the long half-lif...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Arribas, Jose Ramon, Sanyal, Arun J, Soriano, Alex, Chin, Bum Sik, Kalimuddin, Shirin, Schreiber, Stefan, Elboudwarej, Emon, Tian, Yuan, Hyland, Robert H, SenGupta, Devi, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Lübbert, Christoph, Lye, David Chien Boon, Aberg, Judith A, Elorza, Enrique Navas, Tashima, Karen T, McPhail, Mark
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Poster Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776163/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.751
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars